Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 10/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839169 | 0.99 | NPSR1 (0.54) | NPSR1ALDH1A1MTNR1BKEAP1HTR7 | |
| SCHEMBL4838275 | 0.89 | NPSR1 (0.53) | NPSR1ALDH1A1MTNR1BKEAP1NFE2L2 | |
| SCHEMBL4839831 | 0.89 | KCNA3 (0.53) | NPSR1ALDH1A1 | |
| SCHEMBL4838911 | 0.88 | KCNA3 (0.52) | NPSR1ALDH1A1MTNR1B | |
| SCHEMBL4837245 | 0.86 | ALDH1A1 (0.50) | NPSR1ALDH1A1MTNR1BKEAP1NFE2L2 | |
| SCHEMBL4833126 | 0.86 | ALDH1A1 (0.52) | NPSR1ALDH1A1MTNR1BKEAP1NFE2L2 | |
| SCHEMBL4837378 | 0.86 | ALDH1A1 (0.52) | NPSR1ALDH1A1MTNR1BKEAP1NFE2L2 | |
| SCHEMBL4840640 | 0.82 | HTR7 (0.41) | MTNR1BHTR7 | |
| SCHEMBL4838113 | 0.82 | TP53 (0.42) | MTNR1BHTR7 | |
| SCHEMBL4833495 | 0.81 | ALDH1A1 (0.55) | NPSR1ALDH1A1MTNR1BKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384957-B2 | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2008-06-10 | — | — | US | claimed |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2005-03-31 | — | — | US | claimed |
| US-7384957-B2 | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2005-03-31 | — | — | US | disclosed |
| EP-1458714-A1 | 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES | H. Lundbeck A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051869-A1 | 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES | H. LUNDBECK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | KCNJ2, KCNK2, KCNJ11 | NPSR1 167/4885ALDH1A1 639/4885MTNR1B 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.